Clinical Trials Logo

Lymphedema clinical trials

View clinical trials related to Lymphedema.

Filter by:

NCT ID: NCT06374745 Recruiting - Breast Cancer Clinical Trials

An Integrated Algorithm for Surgical Intervention in Chronic Lymphedema After Breast Cancer Treatment: The Basel Lymphedema Protocol

Start date: January 2, 2015
Phase:
Study type: Observational

The primary objective of the investigators is to develop an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. This will be achieved by retrospectively analysing a subgroup of patients who had breast cancer-related surgery prior to lymphedema.

NCT ID: NCT06329167 Recruiting - Clinical trials for Lower Extremity Lymphedema

Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery

Start date: March 25, 2024
Phase: Phase 4
Study type: Interventional

This clinical trial is designed to learn more about treating patients with lower limb lymphoedema following gynaecological surgery. The main question to be answered is To evaluate the efficacy of Daphnetin capsule in the treatment of patients with lower limb lymphedema following gynaecological malignancy surgery. Participants will take Daphnetin capsule 150mg tid (3 capsules/time, 3 times daily) orally at the same time as gradient compression stocking treatment. Researchers will compare 150mg Forte tablets (2 capsules/time, 2 times daily) and gradient compression stockings to see if Daphnetin capsule can be used to treat patients with lower extremity lymphedema following gynaecological malignancy surgery.

NCT ID: NCT06327438 Recruiting - Breast Neoplasms Clinical Trials

Effect of Complex Decongestive Therapy, Cryotherapy and Kinesio Taping in Patients With Post-mastectomy Lymphedema: A Randomized Control Trial

Start date: March 16, 2024
Phase: N/A
Study type: Interventional

To examine the efficacy of complex decongestive therapy (CDT), cryotherapy and kinesio taping (KT) in patients with post-mastectomy lymphedema

NCT ID: NCT06327412 Not yet recruiting - Aerobic Exercise Clinical Trials

The Effects of Aerobic Exercise in Patients With Primary Lower Extremity Lymphedema

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Our aim in this study is to evaluate the effects of lymphedema on exercise capacity, body composition, functional level and quality of life in lymphedema patients with primary lower extremity involvement.

NCT ID: NCT06325618 Recruiting - Clinical trials for Cardiovascular Diseases

Lymphedema, Low-grade Inflammation and the Vasculature in Turner Syndrome

TSCOR_V
Start date: January 8, 2024
Phase:
Study type: Observational

100 women with karyotype verified TS, previously examined at 4 study visits during a 19-year period will be asked to participate in a 5th study visit. Healthy age-matched females will be included as controls in a ratio 2:1. The aim is to examine and quantify the cardiovascular and lymphatic system in women with TS. The investigators will study a possible causal mechanism between the known pathologic phenotype and alterations in these systems to understand, prevent or treat the life-threatening complications in TS.

NCT ID: NCT06324721 Recruiting - Breast Cancer Clinical Trials

Why do Patients Report Lymphedema After Breast Cancer Treatment Without an Objective Measurable Swelling

LymphSens
Start date: March 26, 2024
Phase: N/A
Study type: Interventional

Breast cancer related lymphedema (BCRL) is due to its chronicity and impact an extremely dreaded complication after breast cancer treatment. The prevalence rate of objective arm and trunk/ breast BCRL is declining due to the major shift into the treatment approach of breast cancer. However, the prevalence rate of subjective arm and trunk/ breast BCRL is much higher than that of objective BCRL. Subjective BCRL is defined as the diagnosis of BCRL based on the patient's sensation of a difference in size at the arm and/or trunk without any objectively measurable swelling. At this moment, it is not clear how many breast cancer patients experience subjective arm or trunk/breast BCRL and what the underlying mechanisms may be. Therefore, the investigators hypothesize that four mechanisms might be associated with the presence and the severity of subjective arm or trunk/breast BCRL, including sensory processing problems (1. nociceptive and/or 2. neuropathic and/or 3. central) and the presence of disturbed lymphatic transport without clinical manifestation (4. subclinical BCRL). The investigators will set up a prospective longitudinal study with breast cancer patients to determine the prevalence of subjective and objective arm or trunk/ breast BCRL at 1, 6. and 12 month(s) post-surgery and the transitions between the different types of BCRL and to compare the amount of swelling at arm or trunk/ breast, the presence or severity of subclinical BCRL and peripheral and central sensory processing problems between patients with different types of BCRL. In addition, the present study will be undertaken to determine the contributing factors to the severity of subjective arm or trunk/ breast BCRL within the group of patients with subjective BCRL at different time-points after surgery (at 1, 6. and 12 month(s) post-surgery).

NCT ID: NCT06323200 Completed - Lymphedema Clinical Trials

Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA

LVA
Start date: September 2015
Phase:
Study type: Observational [Patient Registry]

This study aimed to address the impact of lymphedema duration on the quality of lymphatic vessels as well as the outcome after LVA using propensity score matching.

NCT ID: NCT06321653 Recruiting - Breast Cancer Clinical Trials

Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes

AXILL-ART
Start date: April 18, 2019
Phase:
Study type: Observational

In this observational prospective studi patients with invasive breast cancer no more than 5 cm and clinically node negative, scheduled for conservative surgery and Sentinel Node Biopsy (SNB), are enrolled in the protocol if they have 1-2 sentinel lymphnodes (SLNs) with macrometastases. SLN status will be checked on definitive sections.

NCT ID: NCT06321549 Completed - Clinical trials for Breast Reconstruction

New Era of DIEP With Minimally Invasive Mastectomy

Start date: October 3, 2022
Phase:
Study type: Observational

The free deep inferior epigastric artery perforator (DIEP) flap is the gold standard in autologous breast reconstruction. Asian patients often present with a smaller body mass index with relatively insufficient tissue. To restore appropriate symmetry, a larger flap inset ratio must be transferred. Supercharging of the second vein or inclusion of bilateral pedicle is commonly required. Current paradigm shifts in mastectomy has also resulted in more minimally invasive surgeries (MIS) espousing smaller lateral incisions, leading to a significant change in available recipient vessels. This study aimed to demonstrate our experience in changing strategies of DIEP flaps following the evolution of mastectomy techniques. Between October 2008 and March 2022, retrospective data was gathered for 278 patients who underwent breast reconstruction surgery utilizing DIEP flaps by a single plastic surgeon. These patients were divided into two distinct groups based on their operation dates, with November 2018 marking a pivotal moment when the first MIS was introduced.

NCT ID: NCT06306274 Not yet recruiting - Lymphedema Clinical Trials

Topical Tacrolimus for Breast Cancer-related Lymphedema

Start date: May 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to investigate the effect of tacrolimus ointment in women with stage I or II breast cancer-related lymphedema. The main question it aims to answer are: - How tacrolimus affects breast cancer related lymphedema regarding subjective and objective measures (e.g. arm volume, lymphedema index, lymphatic function, and quality of life). - If maintenance treatment is effective. Participants will be treated with either active drug or placebo once daily for six months followed by a six month maintenance periode with treatment twice weekly. Assessments will be performed at baseline, three, six, nine and 12 months.